AVIDITY BIOSC.INC.-,0001

Shareholders of Avidity Biosciences voted at an extraordinary virtual general meeting to approve the merger agreement with Novartis as well as the spin-off and distribution agreement. The main proposal passed with a clear majority (123,351,048 votes in favor, representing about 79.95% of the capital present); an advisory vote on the compensation of named executives was also approved. The distribution of the shares of Atrium Therapeutics to Avidity shareholders remains a condition to be fulfilled for the transaction to close. » Więcej na de.investing.com

Avidity released final results from the Phase‑1/2 MARINA study of delpacibart etedesiran (del‑desiran) in myotonic dystrophy type 1, showing an average reduction in DMPK mRNA of about 40% and improvements in hand function, muscle strength, mobility and patient‑reported outcomes. The treatment had an overall acceptable safety profile; two serious adverse events occurred in higher dose groups and one participant discontinued the study. Del‑desiran is currently being evaluated in the global Phase‑3 HARBOR study, with topline data expected in the second half of 2026. Avidity is trading near its 52‑week high but remains unprofitable, reporting a net loss of roughly $550 million over the past twelve months. » Więcej na de.investing.com

Avidity Biosciences shares rose to an all-time high of $72.63 and show a one-year return of 160.28%; market capitalization is about $10.94 billion. Novartis has agreed to an acquisition of roughly $12 billion and is offering shareholders $72 per share in cash. Analysts see both further upside (price target up to $96) and risks; several firms downgraded the stock to neutral/hold after the announcement. The company also announced a managed access program for delpacibart zotadirsen in Duchenne patients and reports high liquidity (current ratio 11.57). » Więcej na de.investing.com

Avidity Biosciences’ stock hit an all-time high of $72.23 after Novartis agreed to a takeover offer of around $12 billion; shareholders are to receive $72 per share in cash. The sharp price gain reflects strong investor demand, but technical indicators point to an overbought condition. Avidity also reported the launch of a managed-access program for delpacibart zotadirsen in Duchenne muscular dystrophy, while analysts downgraded the stock to neutral/hold after the offer and slightly cut price targets. » Więcej na de.investing.com

Avidity Biosciences’ stock climbed to an all-time high of $71.81 after a year-to-date gain of about 120.96% and a market capitalization of roughly $10.82 billion. The company shows strong short-term liquidity (current ratio 11.57). Avidity launched a managed-access program for the investigational therapy delpacibart zotadirsen and is the subject of a Novartis-proposed acquisition for around $12 billion ($72 per share). Following the takeover announcement, analysts cut their ratings and price targets, while additional Phase‑2/3 biomarker data are expected in 2026. » Więcej na de.investing.com